Literature DB >> 32622568

Commentary: Why does neoadjuvant therapy suddenly make sense for early stage non-small cell lung cancer?

Jessica Donington1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32622568     DOI： 10.1016/j.jtcvs.2020.04.050

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN： 0022-5223            Impact factor:   5.209


× No keyword cloud information.
  1 in total

1.  Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy.

Authors:  Ping Chen; Qing Yang; Yinfeng Li; Xiaomei Jing; Jing Chen
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.